Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study

Abstract

Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated.Methods: PsA patients from 16 Italian Rheumatology Units treated with adalimumab as firstor second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate.Results: From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± Frontiers in Pharmacology | www.frontiersin.org 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2-3.2, p = 0.005).Conclusions: Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.

Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden

“…This explains why ADA is much more prevalent in biologic-naïve patients (91%). The high proportion of first-line ADA patients reflects general clinical practice and has been seen on a European level [ 21 ]. This was accounted for through the adjustment for treatment line.…”

MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics

“…Nrf2 is an increasingly interesting transcriptional factor acting as a key regulator of oxidative stress genes. In DM models, the activation of Nrf2 is enhanced due to excessive production of oxidizing agents [ 81 ]. Fatty acids activated transcriptional factors such as PPARs can demonstrate anti-inflammatory activity and are confirmed to downregulate the expression of proinflammatory genes through transrepressive mechanisms [ 82 ].…”

Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement

“…Etanercept, infliximab, adalimumab, golimumab (GLM), and certolizumab have been demonstrated to be effective in PsA and in distinctive aspects of the disease, as skin disease, peripheral arthritis, enthesitis, and dactylitis. Moreover, their effectiveness was demonstrated in improving quality of life and work ability and in reducing radiographic progression [ 6 ]. GLM is a TNFi approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of active rheumatoid arthritis, active PsA, active ankylosing spondylitis, severe non-radiographic axial SpA, polyarticular juvenile idiopathic arthritis, and moderate to severe active ulcerative colitis [ 7 ].…”